Sonnet BioTherapeutics presented data at the 2025 AACR:IO Conference on its Fully Human Albumin Binding (FHAB) platform, which enhances tumor targeting and retention of immunomodulators. The platform links mono- or bifunctional immunomodulators to an albumin-binding domain, improving the pharmacokinetic profile and reducing toxicity risk. The presentation focused on SON-1010, a rhIL-12 configured with FHAB, and its application in various combination therapies.

This research holds promise for advancing immunotherapy in oncology. The FHAB platform addresses key challenges associated with recombinant interleukins, such as short half-lives and off-target effects, which have historically limited their clinical success. By improving tumor-specific delivery and reducing systemic toxicity, the platform could unlock the therapeutic potential of potent immunomodulators like IL-12, leading to more effective and safer treatments for various cancers.

The presented data highlighted the platform’s ability to increase the half-life and bioactivity of IL-12. This leads to a broader therapeutic index, increased activation of key immune cells (NK, NKT, Th1, and cytotoxic CD8 T cells), and repolarization of immunosuppressive cells within the tumor microenvironment. SON-1010 is currently being investigated in several clinical settings: as a monotherapy, in combination with a checkpoint inhibitor (atezolizumab), in alternation with immunoreactive chemotherapy (trabectedin), and with a chemotherapeutic regimen (NALIRIFOX) for pancreatic ductal adenocarcinoma. Early clinical data from a trial combining SON-1010 with atezolizumab in platinum-resistant ovarian cancer shows a 48% clinical benefit rate, including a partial response in a patient with clear cell sarcoma. Further trials, including one investigating SON-1210 (IL12-FHAB-IL15) in combination with NALIRIFOX for metastatic pancreatic cancer, are planned.

The FHAB platform represents a significant advancement in targeted immunotherapy. The positive early clinical data and the ongoing trials suggest the potential for improved outcomes in patients with various difficult-to-treat cancers. If successful, the platform could usher in a new era of cytokine-based therapies, offering more effective and less toxic treatment options. The continued development of the FHAB platform and the exploration of its application with various immunomodulators and combination therapies will be critical to realizing its full potential.

Source link: https://www.globenewswire.com/news-release/2025/02/26/3032957/0/en/Sonnet-BioTherapeutics-Presents-Compilation-of-Data-Highlighting-the-Potential-of-SON-1010-as-a-Monotherapy-or-a-Combination-Therapy-to-Improve-the-Treatment-of-Solid-Tumors.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.